Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Multiple Myeloma 40Neoplasms, Plasma Cell 5Neoplasms 5Recurrence 4Renal Insufficiency 3Paraproteinemias 3Hematologic Diseases 3Smoldering Multiple Myeloma 2Neoplasms by Histologic Type 2Hematologic Neoplasms 2Blood Protein Disorders 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm, Residual 1Natural Killer/T-cell Lymphoma 1Monoclonal Gammopathy of Undetermined Significance 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Plasma Cell 1Immunoproliferative Disorders 1Immunoglobulin Light-chain Amyloidosis 1Hodgkin Disease 1Cryoglobulinemia, Familial Mixed 1

Interventions

Cyclophosphamide 240Rituximab 187fludarabine phosphate 129Etoposide 110Peripheral Blood Stem Cell Transplantation 108Mycophenolic Acid 94Filgrastim 91Melphalan 90Whole-Body Irradiation 88fludarabine 80Busulfan 80Tacrolimus 71Cytarabine 66Cyclosporine 66Radiotherapy 62Methotrexate 53Antilymphocyte Serum 53Granulocyte Colony-Stimulating Factor 51Vincristine 49Carmustine 48Doxorubicin 41Prednisone 37Thiotepa 33Bendamustine Hydrochloride 32Bortezomib 30Methylprednisolone 29Dexamethasone 28Stem Cell Transplantation 27thymoglobulin 26ibritumomab tiuxetan 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoma, Non-Hodgkin × isatuximab × Clear all
NCT05346809 2025-06-08

Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma

Columbia University

Phase 2 Recruiting
39 enrolled
LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡